| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. | Chief Development Officer | Common Stock | 118,823 | $156,846 | $1.32 | 20 Feb 2026 | Direct |
| AN2 Therapeutics, Inc. | Chief Development Officer | Stock Option (right to buy) | 77,000 | 20 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | 20 Feb 2026 | 2 | $0 | 4 | Chief Development Officer | 23 Feb 2026, 16:35 |
| ANTX | AN2 Therapeutics, Inc. | 05 Jan 2026 | 2 | -$9,332 | 4 | Chief Development Officer | 07 Jan 2026, 20:13 |
| ANTX | AN2 Therapeutics, Inc. | 26 Feb 2025 | 2 | $0 | 4 | Chief Development Officer | 28 Feb 2025, 16:27 |
| ANTX | AN2 Therapeutics, Inc. | 03 Jan 2025 | 1 | -$3,965 | 4 | Chief Development Officer | 07 Jan 2025, 20:00 |
| ANTX | AN2 Therapeutics, Inc. | 15 Mar 2024 | 1 | $0 | 4/A | Chief Development Officer | 29 Mar 2024, 16:16 |
| ANTX | AN2 Therapeutics, Inc. | 15 Mar 2024 | 2 | $0 | 4 | Chief Development Officer | 18 Mar 2024, 19:27 |
| ANTX | AN2 Therapeutics, Inc. | 15 Feb 2023 | 1 | $0 | 4 | Chief Development Officer | 17 Feb 2023, 18:28 |
| ANTX | AN2 Therapeutics, Inc. | 12 May 2022 | 1 | $0 | 4 | Chief Development Officer | 16 May 2022, 21:32 |
| ANTX | AN2 Therapeutics, Inc. | 24 Mar 2022 | 0 | $0 | 3 | Chief Development Officer | 24 Mar 2022, 21:19 |